SCHEMBL2854091

SCHEMBL2854091

CON(C)C(=O)c1nc(C(F)(F)F)n2c1CN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.42
DPP4 P27487 1/20 0.40
GPR119 Q8TDV5 10/20 0.38
LIPG Q9Y5X9 1/20 0.36
HDAC4 P56524 1/20 0.35
PARP1 P09874 1/20 0.34
TLR9 Q9NR96 1/20 0.34
ESR2 Q92731 1/20 0.34
MAPT P10636 1/20 0.33
CYP8B1 Q9UNU6 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE11A Q9HCR9 1/20 0.33
PDE10A Q9Y233 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10025741 0.90 DPP4 (0.40) NR1H2DPP4GPR119LIPGHDAC4
SCHEMBL27791317 0.88 GPR119 (0.35) NR1H2DPP4GPR119LIPGCYP8B1
SCHEMBL14956184 0.86 USP30 (0.39) NR1H2DPP4GPR119LIPGCYP8B1
SCHEMBL2860794 0.84 DPP4 (0.53) NR1H2DPP4GPR119LIPGHDAC4
SCHEMBL2856421 0.84 LIPG (0.42) NR1H2DPP4GPR119LIPGHDAC4
SCHEMBL2863171 0.84 DPP4 (0.41) NR1H2DPP4GPR119LIPGHDAC4
SCHEMBL1174741 0.81 NR1H2 (0.45) NR1H2GPR119
SCHEMBL13175269 0.81 NR1H2 (0.44) NR1H2DPP4GPR119LIPGHDAC4
SCHEMBL2855779 0.81 NR1H2 (0.44) NR1H2DPP4GPR119LIPGHDAC4
SCHEMBL2855793 0.79 DPP4 (0.38) NR1H2DPP4LIPGHDAC4ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2230241-B1 TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF JIANGSU HENGRUI MEDICINE CO (CN) 2014-11-26 EP disclosed
EP-2230241-B1 TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF JIANGSU HENGRUI MEDICINE CO (CN) 2014-11-26 EP disclosed
US-8513411-B2 Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2013-08-20 US disclosed
US-8513411-B2 Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2013-08-20 US disclosed
US-8513411-B2 Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2013-08-20 US disclosed
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-08-30 US disclosed
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-08-30 US disclosed
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-08-30 US disclosed
US-8207161-B2 Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2012-06-26 US disclosed
US-8207161-B2 Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2012-06-26 US disclosed
US-8207161-B2 Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2012-06-26 US disclosed
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2010-10-28 US disclosed
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2010-10-28 US disclosed
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2010-10-28 US disclosed
EP-2230241-A1 TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2010-09-22 EP disclosed
EP-2230241-A1 TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2010-09-22 EP disclosed
CN-101641361-A Tetrahydroimidazo [1, 5-a ] pyrazine derivative, preparation method and application thereof in medicine SHANGHAI HENGRUI PHARM CO LTD 2010-02-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF DPP4, DPP3, DPP7 NR1H2 2937/4885DPP4 1/4885GPR119 579/4885
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 NR1H2 3996/4885DPP4 1/4885GPR119 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.